Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs
- 1 December 2004
- journal article
- research article
- Published by Elsevier in Atherosclerosis
- Vol. 177 (2), 235-243
- https://doi.org/10.1016/j.atherosclerosis.2004.10.001
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Relationship Between Selective Cyclooxygenase-2 Inhibitors and Acute Myocardial Infarction in Older AdultsCirculation, 2004
- Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort studyThe Lancet, 2004
- COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart diseaseThe Lancet, 2002
- Role of Prostacyclin in the Cardiovascular Response to Thromboxane A 2Science, 2002
- Risk of Cardiovascular Events Associated With Selective COX-2 InhibitorsJAMA, 2001
- Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000
- Augmented Expression of Cyclooxygenase-2 in Human Atherosclerotic LesionsThe American Journal of Pathology, 1999
- Cyclooxygenase-2 Is Widely Expressed in Atherosclerotic Lesions Affecting Native and Transplanted Human Coronary Arteries and Colocalizes With Inducible Nitric Oxide Synthase and Nitrotyrosine Particularly in MacrophagesArteriosclerosis, Thrombosis, and Vascular Biology, 1999
- Increased Prostacyclin Biosynthesis in Patients with Severe Atherosclerosis and Platelet ActivationNew England Journal of Medicine, 1984